Madison, WI, January 25, 2020 – Imbed Biosciences Inc. (Imbed), a privately held biotech company emerging as a leader in the advanced wound care, announced today that it has entered an exclusive distribution agreement with Jorgensen Laboratories (“Jorvet”) to distribute its MicroLyte® VET wound dressings to veterinary hospitals and clinics in the U.S. and Canada.
MicroLyte® VET is an FDA-cleared antimicrobial wound dressing that was developed in collaboration with veterinary scientists at the University of Wisconsin-Madison. Unlike traditional antimicrobial dressings, MicroLyte VET conforms intimately to the tissue, providing a scaffold for cell growth and absorbing completely over time. The ultrathin matrix contains ionic and metallic silver that kills bacteria hiding in a wound-bed and provides up to 3 days of sustained antimicrobial activity.
Jorvet manufactures and distributes a variety of products for veterinary care. With a highly experienced sales force, Jorvet works closely with almost all the veterinary distribution companies in North America.
Norm Jorgensen DVM is son of the founder of Jorvet. He is now the VP of Sales and Marketing and is leading the charge of the company’s efforts to become leaders in veterinary wound care. “Things are always changing in the industry, so we’ve always wanted to make sure new technology is available and help the veterinarians understand what’s possible. There are a lot of exciting things happening in wound care, and we’re happy to partner with Imbed because MicroLyte VET is a big part of that.”
As the animal health market grows generally, the overall veterinary wound care market has been projected to reach $1.5 billion by 2025. Imbed’s veterinary business manager William Merrick noted, “with more people working from home, they’re spending more time with their pets who often are suffering from chronic wounds such as lick granulomas or other sores. Partnering with Jorvet means more clinics will learn that MicroLyte VET is not only for clinical wounds but can also help many pet owners who currently are not taking their pet to the veterinarian for those small, yet chronic, wounds.”
“We are excited about this partnership with Jorvet and getting Microlyte Vet in the bags of their seasoned sales team and network. Two of the founders of Imbed are veterinary surgeons, who were also inventors of Microlyte® Matrix technology. So, it makes me proud to be able to realize their vision of getting this next-generation wound dressing into the hands veterinary physicians across the country”, said Ankit Agarwal, founder and CEO of Imbed.
MicroLyte VET will now be available through Jorvet and its distribution partners. Imbed and Jorvet will together be hosting regular educational webinars for veterinarians to share latest tools available in advanced wound care.
Imbed Biosciences Inc. is a privately held biotech company registered with the FDA as a medical device manufacturer with an ISO 13485 certified quality management system. The company has a portfolio of products in development based on its patented Microlyte® Matrix technology for tissue engineering to combat local pain and infections in complex wounds such as burns, chronic ulcers, surgical wounds, epidermolysis bullosa, and colorectal surgeries. Research programs at Imbed are partly funded by SBIR grants from National Institutes of Health (NIH). For more information, please visit www.imbedbio.com, www.MicrolyteMatrix.com or www.MicroLyteVet.com.